Anicells contributes to the fight against Covid-19 as a partner in the Xenothera clinical trial

Although Covid-19 case notification rates have been decreasing for nine weeks now across Europe, the fight against the SARS-CoV-2 virus is not yet won. New ICU admissions are still occurring and 20 people per million die every 14 days.

XENOTHERA, a Nantes-based biotech company, developed one of the most promising anti-Covid-19 antibodies. This protective anti-SARS-CoV-2 polyclonal antibody ‘XAV-19’ is designed to treat patients with moderate Covid-related pneumonia. In particular, it aims at stopping the worsening of the disease and avoiding transfer to the ICU.

A recent press release announced the successful completion of patient enrollment in the second phase of the POLYCOR clinical trial. The anicells team is proud to have contributed to Xenothera’s endeavors. We thank Xenothera for the trust in anicells and for the great collaboration. We look forward to the next steps in the project and we are excited to see the product hit the market soon.